Summit Therapeutics Inc. (SMMT) /
The cash flow of Summit Therapeutics Inc. over the past 8 years
Chart Summit Therapeutics Inc.: operating cash flow, capital expenditures, free cash flow, fiscal 2018–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, Summit Therapeutics Inc.'s operating cash flow was -$322.93M and its capital expenditures $657K, leaving free cash flow of -$323.59M. Free cash flow was below zero in all 8 years shown. It ranged from -$323.59M in fiscal 2025 to -$22.17M in fiscal 2018. Capital expenditures were highest in fiscal 2018, at $668K.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$322.93M | $657K | -$323.59M |
| 2024ended Dec 31, 2024 | -$142.11M | $139K | -$142.25M |
| 2023ended Dec 31, 2023 | -$76.76M | $128K | -$76.89M |
| 2022ended Dec 31, 2022 | -$41.58M | $624K | -$42.21M |
| 2021ended Dec 31, 2021 | -$72.59M | $306K | -$72.89M |
| 2020ended Dec 31, 2020 | -$48.11M | $421K | -$48.53M |
| 2019ended Jan 31, 2019 | -$35.11M | $157K | -$35.26M |
| 2018ended Jan 31, 2018 | -$21.5M | $668K | -$22.17M |
Fiscal years as Summit Therapeutics Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Summit Therapeutics Inc.
- The revenue of Summit Therapeutics Inc.
- The profitability of Summit Therapeutics Inc.
- The debt of Summit Therapeutics Inc.
- All of Summit Therapeutics Inc.'s financials, charted
Companies of a similar size
- DVADAVITA INC.
- WTSWATTS WATER TECHNOLOGIES INC
- FDSFACTSET RESEARCH SYSTEMS INC.
- AITAPPLIED INDUSTRIAL TECHNOLOGIES, INC.
- ALLYAlly Financial Inc.
Not investment advice. This page shows what Summit Therapeutics Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.